1403850-91-8

Basic information

• Product Name: (2S)-N-((3S,6S)-3-(tert-butyl)-1⁹-fluoro-2⁴-(4-(hydroxymethyl)oxazol-2-yl)-5-oxo-1^5a,1^10bdihydro-1⁶H-4-aza-1(10b,2)-benzofuro[2,3-b]indola-2(5,2)-oxazolacycloheptaphane-6-yl)-2-hydroxy-3-methylbutanamide
• CAS NO: 1403850-91-8
• Molecular Weight: 645.688
• Mol File: 1403850-91-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (2S)-N-((3S,6S)-3-(tert-butyl)-1⁹-fluoro-2⁴-(4-(hydroxymethyl)oxazol-2-yl)-5-oxo-1^5a,1^10bdihydro-1⁶H-4-aza-1(10b,2)-benzofuro[2,3-b]indola-2(5,2)-oxazolacycloheptaphane-6-yl)-2-hydroxy-3-methylbutanamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-N-((3S,6S)-3-(tert-butyl)-1⁹-fluoro-2⁴-(4-(hydroxymethyl)oxazol-2-yl)-5-oxo-1^5a,1^10bdihydro-1⁶H-4-aza-1(10b,2)-benzofuro[2,3-b]indola-2(5,2)-oxazolacycloheptaphane-6-yl)-2-hydroxy-3-methylbutanamide(1403850-91-8)
• EPA Substance Registry System: (2S)-N-((3S,6S)-3-(tert-butyl)-1⁹-fluoro-2⁴-(4-(hydroxymethyl)oxazol-2-yl)-5-oxo-1^5a,1^10bdihydro-1⁶H-4-aza-1(10b,2)-benzofuro[2,3-b]indola-2(5,2)-oxazolacycloheptaphane-6-yl)-2-hydroxy-3-methylbutanamide(1403850-91-8)

Safety Data

• Hazardous Substances Data: 1403850-91-8(Hazardous Substances Data)

Usage

Uses

A diazonamide analog for treatment of cancer and other proliferative disorders.

Upstream product

• 17407-55-5 (S)-2-Hydroxy-3-methylbutanoic acid 
• 1403851-26-2 C₃₅H₃₆FN₅O₈ 
• 1403851-25-1 C₃₀H₂₈FN₅O₆ 
• 1403851-24-0 C₃₈H₃₄FN₅O₈ 
• 1403851-23-9 C₃₈H₃₈FN₅O₉ 
• 1403851-22-8 C₃₄H₃₁FN₄O₇ 
• 1403851-21-7 C₃₅H₃₃FN₄O₇ 
• 1403851-19-3 C₃₅H₃₅FN₄O₇ 
• 1403851-20-6 C₁₈H₂₀FN₃O₃ 
• 1422430-43-0 C₂₆H₂₆FN₃O₅ 
• 1403851-18-2 C₂₆H₃₀FN₃O₅ 
• 154-08-5 DL-5-fluorotryptophan 

Relevant articles and documents

Electrolytic macrocyclizations: Scalable synthesis of a diazonamide-based drug development candidate

An electrochemical method to synthesize the core macrolactam of diazonamides is described. Large ring-forming dehydrogenation is initiated by anodic oxidation at a graphite surface. The reaction requires no tailoring of the substrate and occurs at ambient temperature in aqueous DMF in an undivided cell open to air. This unique chemistry has enabled a concise, scalable preparation of DZ-2384; a refined analog of diazonamide A slated for clinical development as a cancer therapeutic.